Tumor cells (oncolytic replication) + PD-1 (via expressed antibody)

Class

Oncolytic herpes simplex virus type 1 (oHSV-1) co-expressing IL-12 and an anti-PD-1 antibody

Pathway

Viral-mediated tumor lysis plus immune checkpoint blockade and IL-12-driven NK/CTL activation

Notes

original target text: Tumor cells (oncolytic replication) + PD-1 (via expressed antibody) + IL-12 pathway

This mechanism combines three complementary anti-cancer strategies in a single engineered virus. The backbone is an oncolytic herpes simplex virus type 1 (oHSV-1), a virus modified to preferentially replicate within tumor cells while sparing normal tissue, causing direct tumor cell lysis and releasing tumor antigens that can prime the immune system. Built into this virus are genes encoding interleukin-12 (IL-12), a cytokine that stimulates natural killer (NK) cells and cytotoxic T lymphocytes, and an antibody fragment targeting PD-1, a checkpoint receptor that normally restrains T cell activity. By expressing these components locally at the tumor site rather than administering them systemically, the approach aims to convert immunologically inactive ("cold") tumors into ones infiltrated by activated immune cells ("hot"), while limiting the toxicity associated with systemic IL-12 or checkpoint antibody exposure. This mechanism is broadly relevant across solid tumors that resist immune attack due to poor T cell infiltration or checkpoint-mediated suppression, and it illustrates a rationale in oncology: layering direct cytotoxicity, innate immune activation, and checkpoint blockade to produce a more durable, self-amplifying antitumor immune response than any single modality alone.